We are committed to improving health and well-being around the world. From developing new therapies that treat and prevent disease to helping people in need, we are guided by a rich legacy and inspired by a shared vision.
Humans for Health Curiosity, inventiveness, and a passion for excellence. These are qualities that drive Merck people to discover what’s possible as they work to help improve health around the world.
Senior vice president, Product Development & Supply, Aventis Pharmaceuticals, 2003-2005
Robert M. Davis
Executive Vice President, Chief Financial Officer and Global Services
Executive vice president, chief financial officer and global services, Merck & Co., Inc., 2016
Executive vice president and chief financial officer, Merck & Co., Inc., 2014-2016
Corporate vice president and president, Baxter Medical Products, 2010-2014
Corporate vice president and chief financial officer, Baxter Healthcare, 2006-2010; treasurer, Baxter Healthcare, 2004-2006; Director of Corporate Financial Planning, Eli Lilly and Company, 2002-2004; assistant treasurer and various financial positions, Eli Lilly and Company, 1990-2002
Richard R. DeLuca Jr.
Executive Vice President and President, Merck Animal Health
Executive vice president and president, Merck Animal Health, 2011
President, Wyeth's Fort Dodge Animal Health division, 2007-2010
Chief operating officer, Fort Dodge, 2006-2007; executive vice president and chief financial officer, 2002-2006
Julie L. Gerberding, M.D., M.P.H.
Executive Vice President, Strategic Communications, Global Public Policy and Population Health
Executive vice president, Strategic Communications, Global Public Policy and Population Health, Merck & Co., Inc., 2014
President, Merck Vaccines, 2010-2014
Co-Chair, Board of Directors, Sanofi Pasteur MSD Joint Venture, 2010-present
Director, Centers for Disease Control and Prevention (CDC), 2002-2009
Director, Division of Healthcare Quality Promotion, CDC, 1998-2002
Adjunct Associate Clinical Professor of Medicine in Infectious Disease, University of California, San Francisco, 2002-present
Mirian M. Graddick-Weir
Executive Vice President, Human Resources
Executive vice president, Human Resources, Merck & Co., Inc., 2008
Senior vice president, Human Resources, Merck & Co., Inc., 2006-2007
Executive vice president, Human Resources and Employee Communications, AT&T, 2004-2006
Executive vice president, Human Resources, AT&T, 1999-2004
Chief human resources officer, Consumer Services Company, AT&T, 1998-1999
Michael J. Holston
Executive Vice President and General Counsel
Executive vice president and general counsel, Merck & Co., Inc., 2015
Executive vice president and chief ethics and compliance officer, Merck & Co., Inc., 2012
Executive vice president, general counsel and board secretary for Hewlett-Packard Company, 2007-2012
Partner, Litigation Department at Morgan, Lewis & Bockius LLP, 2005-2007
Partner, Litigation Department at Drinker, Biddle & Reath, 1993-2005
U.S. Department of Justice, Assistant U.S. Attorney, Criminal Division, Eastern District of Pennsylvania, 1990-1993
Roger M. Perlmutter, M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
Executive vice president and president, Merck Research Laboratories, 2013
Executive vice president and head of Research and Development, Amgen Inc., 2001-2012
Executive vice president of Worldwide Basic Research and Preclinical Development, Merck Research Laboratories, 1998-2001; senior vice president, Merck Research Laboratories, 1997-1998
Professor, Departments of Immunology, Biochemistry and Medicine, University of Washington, 1991-1997
Michael Rosenblatt, M.D.
Executive Vice President and Chief Medical Officer
Executive vice president and chief medical officer, Merck & Co., Inc., 2009
Dean, Tufts University School of Medicine, 2003-2009
George R. Minot Professor of Medicine at Harvard Medical School 1998-2003; Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center, 2001-2003;
Harvard faculty dean and senior vice president for Academic Programs at CareGroup and Beth Israel Deaconess Medical Center, 1996-2000
Director, Harvard-MIT Division of Health Sciences and Technology, 1992-1998
Senior vice president for research, Merck & Co., Inc., 1989-1992; vice president, Biological Research and Molecular Biology, 1984-1989
Adam H. Schechter
Executive Vice President and President, Global Human Health
Executive vice president and president, Global Human Health, Merck & Co., Inc., 2010
President, Global Pharmaceuticals, 2007-2010 and Integration Officer, Merck & Co., Inc., 2009-2010
President, U.S. Human Health, Merck & Co., Inc., 2006-2007
Senior vice president and general manager, U.S. Osteoporosis, Respiratory and Neuroscience, Merck & Co., Inc., 2005-2006
CODE OF CONDUCT: OUR VALUES AND STANDARDS
Our code of conduct reflects our corporate values and guides our day-to-day decision making.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.